#Serum Institute of India (SII)

[integrimedical]

SII to acquire 20 pc stake in IntegriMedical

SIIs expertise in vaccine manufacturing and global distribution will be invaluable as we work towards making our technology more widely accessible to patients worldwide, IntegriMedical Managing Director Sarvesh Mutha said. N-FIS will be available in the Indian private market, offering patients and healthcare providers an alternative to traditional needle-based injections, SII said. The technologys advantages include the elimination of needle-phobia, alleviation of pain during administration, convenience of use, and prevention of needle-stick injuries and cross-contamination, it added.

Vaccines manufacturer Serum Institute of India (SII) on Friday said it is acquiring 20 per cent stake in IntegriMedical, to advance needle-free injection system technology.

IntegriMedical has developed a US patented needle-free Injection System (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs, Serum Institute of India (SII) said in a statement.

Read more@ https://www.devdiscourse.com/article/health/2941569-sii-to-acquire-20-pc-stake-in-integrimedical

[starbiopic]

Natasha Poonawalla: The Powerhouse Behind the Poonawalla Empire

The recent buzz about Adar Poonawalla’s acquisition of a 50% stake in Karan Johar’s Dharma Productions has everyone talking, and along with it, the name Natasha Poonawalla is making headlines. While many know her for her bold fashion choices, Natasha is a business leader in her own right, standing as the Executive Director of the Serum Institute of India (SII) and Chairperson of the Vailo…

[decentralvaccine]

Top Drugmaker Buys 50% Stake In Bollywood Studio

India's top vaccine maker has bought a 50% stake in a major Bollywood production company known for making popular films.

Adar Poonawalla’s Serene Production will invest 10bn rupees ($119m; £91.3m) in Karan Johar's Dharma Productions and Dharmatic Entertainment, his company said.

Poonawalla also heads the Serum Institute of India (SII), the world's largest vaccine maker by number of doses, which produced millions of Covid-19 shots for India and many other countries during the pandemic.

Poonawalla’s investment in the entertainment company is a significant move at a time when Bollywood is struggling to overcome lean times since the Covid-19 pandemic shut cinema.

[werindialive]

Why spend so much on Maldives when India has Andaman and Lakshadweep, ask Indian businessmen

The tweets from now suspended Maldives government ministers sparked a fresh controversy as the ministers criticized Indian government, Indians and PM Modi through their social media accounts. The tweets were in response to Prime Minister Modi’s endorsement of Lakshadweep as a tourist destination.

Now, the Indian business leaders have come up with their doubts for why Indian tourists pay so much to visit the island nation when India itself has such beautiful islands including Lakshadweep and Andaman.

Radhika Gupta, MD and CEO, Edelweiss Mutual Fund took to X to state her doubts. “I am obsessed with the potential of Indian tourism…the answer is (1) infrastructure and (2) marketing. The PM’s recent visit has put the spotlight on these destinations. Our hotel brands have shown us time and again that we know how to do luxury like no one else. Let’s take the best of Indian hospitality to build a world class tourism experience,” she posted.

“Our country has so many magnificent tourist destinations, with unimaginable potential; yet to be fully explored. Can any of you guess this Indian tourist haven, just from the pictures I’ve posted?” posted Adar Poonawalla, CEO, Serum Institute of India (SII).

EaseMyTrip also made an announcement stating that it is putting all the flights to Maldives on hold. “In solidarity with our nation, @EasMyTrip has suspended all Maldives flight bookings,” Co-founder and CEO Nishant Pitti posted on his social media account.

Many Indians- including sportsperson, actors and politicians- were outraged by the act of the deputy ministers. Several celebrities and people of status even cancelled their booking to Maldives to condemned the act by Maldives politicians.

For latest news India in Hindi, please subscribe to our newsletter.

[nandedlive]

Dengue vaccine | मोठी बातमी! आता डेंग्यूचा होणार अंत; वर्षभरात येणारं लस, सायरस पूनावाला यांची घोषणा

Dengue vaccine | भारतातील लस किंग सायरस पूनावाला यांनी एक मोठे विधान केले आहे ज्यात त्यांनी म्हटले आहे की ते एका वर्षात डेंग्यूवर बरा करणार आहेत. सिरम इन्स्टिट्यूटचे चेअरमन सायरस पूनावाला यांनी सांगितले की, वर्षभरात आम्ही डेंग्यू उपचार आणि डेंग्यूची लस (Dengue vaccine ) विकसित करू. आफ्रिकन देश आणि भारतात या नवीन लसीची खूप गरज आहे, जिथे लाखो लोकांना या आजाराची लागण होत आहे. Malaria vaccine Covishield च्या यशानंतर, SII जगात प्रथमच मलेरियाची लस लॉन्च करणार आहे. या लसीची आफ्रिकन देशांमध्ये आणि भारताच्या अंतर्गत भागातही नितांत गरज आहे, जिथे लाखो लोकांना या सामग्रीमुळे संसर्ग होत आहे. मोठ्या संख्येने स्त्रियांना संक्रमित करणाऱ्या रोगा��ाठी एक लस आहे, ही एक लस आहे जी गर्भाशयाला संक्रमित करते. Work started at SII Serum Institute of India एसआयआय सीरम इन्स्टिट्यूट ऑफ इंडियामध्ये काम सुरू सायरस पूनावाला यांनी पत्रकार परिषदेत डेंग्यूसंदर्भात मोठी घोषणा केली. पूनावाला यांनी डेंग्यूच्या लसीची नितांत गरज स���ंगितली. सिरम इन्स्टिट्यूट डेंग्यूच्या लसीवर दीर्घकाळापासून काम करत आहे. आफ्रिकन देशांव्यतिरिक्त, संपूर्ण आशिया आणि भारतात डेंग्यूमुळे बरेच लोक मरतात. अलीकडेच, सीरम इन्स्टिट्यूटच्या अहवालाने निष्कर्ष काढला की डेंग्यू लसीचा एकच डोस प्रौढांमध्ये सुरक्षित आणि चांगल्या प्रकारे सहन केला जातो. सिरम इन्स्टिट्यूटमध्ये डेंग्यूची लस तयार करण्यासाठी सतत चाचणी आणि काम केले जात आहे. There will be a vaccine for all four types या चारही प्रकारांसाठी लस असेल सिरम इन्स्टिट्यूट ऑफ इंडियाचे अध्यक्ष सायरस पूनावाला यांनी डेंग्यूची लस वर्षभरात आणण्याची घोषणा केली आहे. यामध्ये डेंग्यूच्या चारही प्रकारांवर उपचार केले जातील. सीरम इन्स्टिट्यूट लवकरच लस बाजारात आणण्याच्या प्रक्रियेकडे पावले टाकू शकते. देशात औषधाच्या प्रसारासाठी जलदगती मंजुरीसाठी विज्ञान आणि तंत्रज्ञान मंत्रालयाकडे अर्ज करण्यासारख्या गोष्टींचा यात समावेश आहे. सीरमने आपल्या तंत्रज्ञानाचा वापर करण्यासाठी यूएस स्थित बायोटेक्नॉलॉजी कंपनी (व्हिस्टेरा) सोबत सहकार्य केले आहे. जागतिक आरोग्य संघटनेच्या (WHO) आकडेवारीनुसार, दरवर्षी 10 ते 40 कोटी डेंग्यू तापाचे रुग्ण आढळतात Read the full article

[ameyawdebrah]

Ghana approves second malaria vaccine

Ghana – one of the first countries to vaccinate against malaria through the pilot malaria vaccine implementation programme (MVIP), supported by Gavi – has granted full national licensure to the R21/Matrix-M™ malaria vaccine, developed by the University of Oxford and manufactured and scaled up by the Serum Institute of India (SII). (more…) “”

[innovationtrends]

Pharmaceutical Fluid Handling Market Size, Growth, Industry Trends, Global Demand, and Forecast 2023-2028

The pharmaceutical fluid handling market is projected to reach US$ 14,209.40 million by 2028; registering at a CAGR of 4.7% from 2022 to 2028, according to a new research study conducted by The Insight Partners.

Equipment Segment Dominated Pharmaceutical Fluid Handling Market in 2021

Increasing drug production and growing adoption of single-use systems in the pharmaceutical industry are the factors that contribute to the pharmaceutical fluid handling market growth. However, high price of failed clinical trials restricts the market growth.

Grab PDF to Know More (Including Table, Full TOC and Figures) @ https://www.theinsightpartners.com/sample/TIPRE00029767/  

Increase in Vaccine Production Provides Opportunity to Pharmaceutical Fluid Handling Market

Vaccines strengthen the immune system of different age groups, providing protection against infectious diseases. In the past few decades, effective immunization has eliminated polio and smallpox, which registered high mortality rates. In recent years, there has been an increase in vaccination demand due to the rising incidences of viral and bacterial infectious diseases. Further, government foundations, hospitals, and pharmaceutical companies are focusing on regular vaccine administration by providing cost-effective immunization globally. This is boosting the demand for vaccine production, which is likely to promote the growth of the pharmaceutical fluid handling market. For instance, the Indian Universal Immunization Programme (UPI) rolled out its pneumococcal conjugate vaccine to 21 lakh children. Additionally, government funding and company investments are stimulating R&D to launch new products. According to World Health Organization, in November 2022, a total of 16 billion vaccine doses, valued at US$ 141 billion, were supplied in 2021, which is approximately three times more than the doses supplied in 2019, i.e., 5.8 billion. The Serum Institute of India (SII) postponed HPV vaccine production for two years due to the focus on the development of COVID-19 vaccines; however, it will begin supplying HPV vaccine to the Government of India by 2023 in small quantities. Thus, an increase in vaccine production is anticipated to create an opportunity for the pharmaceutical fluid handling market during the forecast period.

Based on offering, the global pharmaceutical fluid handling market is segmented into equipment and solutions and services. In 2021, the equipment segment held the largest share of the market, and it is expected to register the highest CAGR during 2022–2028. The equipment & solutions segment is further segmented into metering pumps and capsule equipment (filling/sorting), mixing equipment and valves, thermal processing equipment (coolers/chillers/dryers/heat-exchangers), x-ray inspection systems, tanks for holding liquids and flow control products, filters/filter sets (pre-filters/ sterilizing grade filters/ virus filters), powder handling bags, sterile connectors/disconnectors and membrane filter cartridges, and others. Based on tubing, the market is segmented into TPE, PVC, and silicone.

CIRCOR International Inc, Parker Hannifin Corp, Danaher Corp, Spirax Sarco Engineering plc, Merck KGaA, Rochling SE & Co KG, RAUMEDIC AG, Tef Cap Industries Inc, Fraser Ross Ltd, and Australian Fluid Handling Pty Ltd are the key companies operating in the pharmaceutical fluid handling market.

The report segments the pharmaceutical fluid handling market as follows:

The pharmaceutical fluid handling market is segmented on the basis of offering, tubing, application, usage, end user, and geography. Based on offering, the market is segmented into equipment & solutions and services. Based on tubing, the market is segmented into TPE, PVC, and silicone. Based on application, the market is segmented into fluid handling and management, fluid preparation, integration and automation, aseptic processing, buffer management, and others. Based on usage, the market is segmented into cough syrup, intravenous products, complex APIs, and others. Based on end user, the market is segmented into biotechnology companies, pharmaceutical and medical companies, and others.

In terms of geography, the pharmaceutical fluid handling market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

About US

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

Contact US

Contact Person : Sameer Joshi .

Phone : +1-646-491-9876

E-mail : sales@theinsightpartners.com

[news24fr]

Le Serum Institute of India s'emploie à commercialiser ses deux vaccins clés contre le Covid - Covovax et Covishield - en Chine, qui connaît une résurgence de la pandémie. "Il est très important pour le monde de revenir à ses problèmes de chaîne d'approvisionnement et d'investissement… (donc) il vaut mieux pour le monde que la Chine se remette de cela", a déclaré le chef du SII, Adar Ponawala, à NDTV dans une interview exclusive aujourd'hui. "Nous essayons de nous engager avec la Chine et de leur dire de mettre de côté les différences politiques, les problèmes et les appréhensions et de prendre certains des vaccins occidentaux comme rappel", a-t-il déclaré. Interrogé sur la réponse de la Chine, il a déclaré : "Je pense qu'ils décident de la direction qu'ils veulent prendre... J'espère juste qu'ils décideront rapidement d'une manière ou d'une autre". La nouvelle épidémie en Chine qui a commencé l'année dernière a été attribuée à un cocktail de virus par des experts indiens de la santé. Dans une interview avec NDTV l'année dernière, NK Arora, le chef du panel Covid du Centre, a déclaré: "En Chine, ils n'ont jamais été exposés au virus auparavant, et le vaccin qu'ils ont reçu est probablement moins efficace. La plupart d'entre eux ont reçu trois à quatre doses". M. Poonawalla a déclaré à NDTV que Covovax a fait ses preuves et fonctionne bien contre Omicron. Sa réponse est deux ou trois fois supérieure à celle même de Covishield – l'un des deux vaccins introduits pour la première fois en Inde et dans de nombreux autres pays. Le nouveau vaccin, a déclaré M. Poonawalla, coûtera environ 200 à 300 Rs et sera bientôt sur l'application CoWin du Centre. SII, a déclaré M. Poonawalla, a également soumis des données sur son vaccin contre le paludisme à l'Organisation mondiale de la santé. Le vaccin, a-t-il dit, s'est révélé efficace dans plus de 77% des cas et ils prévoient de le déployer d'ici la fin de l'année en Afrique. Le plus grand fabricant de vaccins en Inde, SII travaille également sur un vaccin contre la dengue, qui est en phase 2-3 d'essais cliniques. Le vaccin, à administrer en trois doses, pourra être prêt dans deux ans, a-t-il ajouté.

[integrimedical]

SII to acquire 20 pc stake in IntegriMedical

SIIs expertise in vaccine manufacturing and global distribution will be invaluable as we work towards making our technology more widely accessible to patients worldwide, IntegriMedical Managing Director Sarvesh Mutha said.N-FIS will be available in the Indian private market, offering patients and healthcare providers an alternative to traditional needle-based injections, SII said.The technologys advantages include the elimination of needle-phobia, alleviation of pain during administration, convenience of use, and prevention of needle-stick injuries and cross-contamination, it added.

Vaccines manufacturer Serum Institute of India (SII) on Friday said it is acquiring 20 per cent stake in IntegriMedical, to advance needle-free injection system technology.

Read more@ https://www.devdiscourse.com/article/health/2941569-sii-to-acquire-20-pc-stake-in-integrimedical

[starbiopic]

Adar Poonawalla Net Worth: ₹1.07 Lakh Crore Tycoon Buys 50% Stake in Dharma Productions

Adar Poonawalla, CEO of the Serum Institute of India (SII), has acquired 50% ownership of Dharma Productions, the film company led by Karan Johar. Through a ₹1,000 crore investment by his Sirin Productions, Poonawalla now holds an equal stake in Dharma, valued at ₹2,000 crore. This collaboration aims to create diverse content, expanding the reach of Dharma Productions beyond Bollywood films. Who…

[newswireml]

Poonawalla gets Patangrao Kadam award, Maha Dy CM hails SII for vaccine#Poonawalla #Patangrao #Kadam #award #Maha #hails #SII #vaccine

Poonawalla gets Patangrao Kadam award, Maha Dy CM hails SII for vaccine#Poonawalla #Patangrao #Kadam #award #Maha #hails #SII #vaccine

Maharashtra Deputy Chief Minister Devendra Fadnavis on Sunday lauded vaccine manufacturer Serum Institute of India and its CEO Adar Poonwalla for their contribution in the fight against COVID-19. He was speaking at the inauguration of Bharti Super Specialty Hospital at Bharti Vidyapeeth where Poonwalla was conferred with the first Dr Patangrao Kadam Memorial Award. “I am very happy we got the…

[decentralvaccine]

Children In Ivory Coast Receive New Doses Of Malaria Vaccine

—

Children in Ivory Coast received the first doses of a new, relatively cheap malaria vaccine on Monday, a step that has been hailed as a major milestone in the battle against one of the world’s most deadly diseases.

The R21 vaccine, developed by the Jenner Institute at the University of Oxford and the Serum Institute of India (SII), has been sent to several African countries and will also be administered in South Sudan Tuesday, the University of Oxford said in a statement sent to CNN.

[arun-pratap-singh]

Serum Institute to provide 2 crore Covishield doses to central govt free of cost

Serum Institute to provide 2 crore Covishield doses to central govt free of cost

The Serum Institute of India (SII) has offered two crore doses of Covishield vaccine to the central government free of cost amid a rise in COVID-19 cases in some countries, official sources said on Wednesday. According to an official source, Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute, has written to the Health Ministry offering the doses worth Rs…

[espnnews2h]

NTAGI chief, Health News, ET HealthWorld

NTAGI chief, Health News, ET HealthWorld

New Delhi: India would be in a position to roll out the indigenously developed Human Papillomavirus Vaccine (HPV) against cervical cancer for girls in the age group of 9-14 under the National Immunisation Programme by mid-2023, NTAGI chairperson Dr N K Arora said. The CERVAVAC vaccine is likely to be launched by the Serum Institute of India (SII) in April next year and will be available at a much…